EUVIMEDEUVIMED entdecken
Crossref

Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics

Parnian Mehinrad, Ahmed Abdelfattah, Sams M A Sadat, Tanin Shafaati, Ahmed H Elmenoufy, David Jay, Frederick West, Michael Weinfeld iD, Afsaneh Lavasanifar iD

Drug Delivery and Translational Research · 2025

DOI: 10.1007/s13346-024-01782-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Parnian Mehinrad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Endonucleases, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Canadian Institute of Health Research, Alberta Cancer foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, a novel inhibitor of ERCC1/XPF heterodimerization, A4, was used as an inhibitor of repair for DNA damage by platinum-based chemotherapeutics. Nano-formulations of A4 were developed, using self-assembly of the following block copolymers: methoxy-poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) (PEO-b-PBCL), methoxy-poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL), or methoxy-poly(ethylene oxide)-block-poly (D, L, lactide) (PEO-b-PDLA 50-50). The nano-formulations were characterized for their average diameter, polydispersity, morphology, A4 encapsulation and in vitro release. The activity of A4 and its nano-formulation on the inhibition of ERCC1/XPF dimerization was investigated. The cytotoxicity of carboplatin and oxaliplatin in colorectal cancer (CRC) cell lines, without or with pre-treatment with A4 or its nanoparticle formulation was assessed by conducting colony forming as well as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays. Among the three nano-formulations of A4 under study, optimum properties were achieved with PEO-b-PBCL nanocarriers, showing an encapsulation efficiency of 83.1 ± 5.83%, loading content of 11.5 ± 0.37 w/w %, < 50% drug release within 24 hs, and an average diameter of < 150 nm. The chemo sensitizing effect of A4 and its nano-encapsulated counterparts were more noticeable when A4 was combined with carboplatin versus oxaliplatin. The results of cytotoxicity studies in HCT116 XPF-/- cells confirmed the specificity of A4 through an XPF-dependent mechanism in the sensitization of these cells to carboplatin at concentrations below 0.5 μM. The result of the study shows great potential for A4 and its PEO-b-PBCL nano-formulation in sensitization of CRC to platinum-based chemotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsEndonucleasesColorectal NeoplasmsAntineoplastic AgentsCarboplatinOrganoplatinum CompoundsHumansOxaliplatinCell Line, TumorCell Survival

Stichwörter der Autor:innen

CarboplatinColorectal cancerDNA repairERCC1NanoparticlesXPF

Substanzen

DNA-Binding ProteinsEndonucleasesERCC1 protein, humanOxaliplatinAntineoplastic AgentsCarboplatinxeroderma pigmentosum group F proteinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
  • Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt.
  • Department of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB, Canada.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Misr University for Science and Technology, P.O. Box 77, 6th of October City, 12568, Egypt.
  • Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. mweinfel@ualberta.ca.

ORCID-Profile: Michael Weinfeld, Afsaneh Lavasanifar

Förderung

  • Canadian Institute of Health Research
  • Alberta Cancer foundation

Zitieren

APA

Mehinrad, P., Abdelfattah, A., Sadat, S. M. A., Shafaati, T., Elmenoufy, A. H., Jay, D., West, F., Weinfeld, M., & Lavasanifar, A. (2025). Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01782-9

Vancouver

Mehinrad P, Abdelfattah A, Sadat SMA, Shafaati T, Elmenoufy AH, Jay D, et al. Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01782-9

BibTeX
@article{Mehinrad2025,
  author = {Mehinrad, Parnian and Abdelfattah, Ahmed and Sadat, Sams M A and Shafaati, Tanin and Elmenoufy, Ahmed H and Jay, David and West, Frederick and Weinfeld, Michael and Lavasanifar, Afsaneh},
  title = {Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  doi = {10.1007/s13346-024-01782-9}
}
Kostenlos starten →